Two early stage clinical trials have reported encouraging results, both of which had options to enroll subjects with central nervous system (CNS) metastases. HER2CLIMB is a Phase 2 randomized, double-blinded, placebo-controlled study of<unk>  in combination with trastuzumab and capecitabine in patients with pretreated, unresectable locally advanced or metastatic HER2-positive breast cancer.
Tucatinib
Neratinib
Fostamatinib
Lapatinib
Ponatinib
Dasatinib
Capmatinib
Pemigatinib